Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus low molecular-weight heparin (LMWH) for the treatment of cancer associated thrombosis (CAT)
Publication
, Conference
Li, A; Manohar, P; Garcia, D; Lyman, G; Steuten, L
Published in: HAEMOPHILIA
2019
Duke Scholars
Published In
HAEMOPHILIA
EISSN
1365-2516
ISSN
1351-8216
Publication Date
2019
Volume
25
Start / End Page
39 / 40
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Li, A., Manohar, P., Garcia, D., Lyman, G., & Steuten, L. (2019). Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus low molecular-weight heparin (LMWH) for the treatment of cancer associated thrombosis (CAT). In HAEMOPHILIA (Vol. 25, pp. 39–40).
Li, A., P. Manohar, D. Garcia, G. Lyman, and L. Steuten. “Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus low molecular-weight heparin (LMWH) for the treatment of cancer associated thrombosis (CAT).” In HAEMOPHILIA, 25:39–40, 2019.
Li A, Manohar P, Garcia D, Lyman G, Steuten L. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus low molecular-weight heparin (LMWH) for the treatment of cancer associated thrombosis (CAT). In: HAEMOPHILIA. 2019. p. 39–40.
Li, A., et al. “Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus low molecular-weight heparin (LMWH) for the treatment of cancer associated thrombosis (CAT).” HAEMOPHILIA, vol. 25, 2019, pp. 39–40.
Li A, Manohar P, Garcia D, Lyman G, Steuten L. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus low molecular-weight heparin (LMWH) for the treatment of cancer associated thrombosis (CAT). HAEMOPHILIA. 2019. p. 39–40.
Published In
HAEMOPHILIA
EISSN
1365-2516
ISSN
1351-8216
Publication Date
2019
Volume
25
Start / End Page
39 / 40
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 1103 Clinical Sciences